Roche's Tecentriq gains new first-line lung cancer use

Roche has an inroad into the lucrative first-line lung cancer market after its immunotherapy Tecentriq gained FDA approval in a subset of patients. 

Celgene investors’ CVR payment looks rocky, as FDA rejects i...

The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right (CVR) deal with Bristol-Myers Squibb have risen sharply, aft

Concerns over BMS and Celgene merger payout as FDA extends d...

Bristol-Myers Squibb’s risky three-drug bet with former shareholders in Celgene is still on – but it could be a close-run thing after the FDA extended the review of a cancer cell therapy cl

CHMP backs BMS’ first-in-class anaemia drug Reblozyl

BMS gets an important win for Opdivo combination in kidney c...

BMS eyes August FDA verdict for Opdivo/Yervoy in first-line ...